Braveheart Bio, Inc. (BRVE)

Price$26.74Cached quoteAs of 2026-09-05 04:00 UTC

AI: Overvalued

Price checkBRVE trades at a rich post-IPO valuation despite having no commercial revenue yet.

Using roughly 90.0 million shares outstanding reported after the IPO, the equity value is about $2.6 billion. After subtracting approximately $527 million of pro forma cash, enterprise value—market value minus cash—is about $2.1 billion. The stock is also about 61% above its IPO issue level. With no product revenue or meaningful earnings multiple, valuation rests almost entirely on future BHB-1893 success, making the present risk-adjusted setup look expensive.

Big pictureBraveheart has ample liquidity and little balance-sheet debt, but a concentrated late-stage biotech risk profile.

Braveheart Bio, Inc. is listed on the Nasdaq Global Market as BRVE and remains a clinical-stage company. Second-quarter net loss was about $15.0 million, while cash and equivalents were $122.8 million before the August IPO; including IPO net proceeds, cash would have been about $527.3 million. Management expects this to fund operations into 2029. June liabilities were only about $9.3 million and no traditional borrowings were listed, so near-term financing pressure is low. The business is not economically cyclical; clinical and regulatory milestones drive value instead.

Business strengthPromising Phase 2 data and two Phase 3 paths create meaningful upside if differentiation holds.

BHB-1893 has shown encouraging signals in both obstructive and non-obstructive hypertrophic cardiomyopathy. In obstructive disease, earlier Phase 2 data showed rapid gradient reduction and a high complete-response rate; in non-obstructive disease, the randomized Phase 2 study showed biomarker, structural, symptom, and exercise improvements. That supports a potentially broad HCM opportunity. However, the evidence still comes from relatively small studies, approved competitors already exist in obstructive HCM, and Braveheart owes Hengrui future milestones plus 5% to 10% royalties on sales.

What could change the storyPhase 3 replication could justify the premium; weaker efficacy, safety, or uptake would expose valuation risk.

The bull case assumes LIONHEART-HCM reproduces strong Phase 2 efficacy with a differentiated safety and monitoring profile, NOBLEHEART-HCM starts as planned in the first half of 2027, and BHB-1893 wins meaningful share across two indications. The bear case is that larger trials show smaller benefits, problematic ejection-fraction reductions, delays, or commercial resistance against established myosin inhibitors. IPO proceeds are allocated mainly to both Phase 3 programs and supporting research operations. Dilution risk is lower near term, but equity plans can expand and longer timelines could still require additional shares.

AI: News

Phase 3 program advancesBraveheart reported second-quarter results and confirmed its lead HCM program is moving into pivotal development.

On September 8, Braveheart said it had initiated the global LIONHEART-HCM Phase 3 study in obstructive HCM, with sites activating and patients screening. The company expects the first patient to be dosed in 2026 and an interim analysis in the second half of 2027. It also said the U.S. IND for non-obstructive HCM is active and NOBLEHEART-HCM is planned to start in the first half of 2027.

IPO strengthens balance sheetAugust’s upsized IPO added substantial cash and reduced near-term dependence on another financing round.

On August 7, Braveheart closed its upsized initial public offering, selling 24,437,500 newly issued common shares after underwriters fully exercised their option. Gross proceeds were approximately $439.9 million, and the later quarterly update put net proceeds at about $404.5 million. Because all shares were issued by the company, the transaction meaningfully increased the share count, but it also gave management enough stated liquidity to fund the current operating plan into 2029.

Non-obstructive data positiveMay Phase 2 results showed broad efficacy signals, while dose reductions highlighted safety still needs confirmation.

On May 11, Braveheart and Hengrui reported a randomized Phase 2 study in 84 adults with symptomatic non-obstructive HCM. BHB-1893 produced significant reductions in cardiac biomarkers and improvements in heart structure, symptoms, and exercise capacity versus placebo. The treatment was generally well tolerated, but four treated patients had temporary ejection-fraction declines below 50% and required dose reductions. The findings supported Braveheart’s plan for a global registrational study.

Loading local price history

Revenue

No reported data

Net income

2025

Free cash flow

No reported data

Total cash / debt

CashTotal debt

2025

Financial statements

	2025
Research & development	$61.4M
Operating income	−$66.7M
Net income	−$66.1M
Basic EPSper basic share	-$5.32
Diluted EPSper diluted share	-$17.20

Review official source filings ↗

Owners

Reported shareholders

Ownership data is not available for this listing yet.

Insider buys & sells

Jul 1, 2024–Jun 30, 2026

Buys0$0.00 disclosed value

Sells (SEC code S)0$0.00 disclosed value

No insider transactions transactions were reported in the stored SEC coverage.

Review ownership filings at SEC.gov ↗

Community posts

View community

It’s quiet here.

No posts about BRVE yet. Start the conversation.

Write the first post